Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 10/2013

01-10-2013 | Original paper

An institutional strategy to increase minority recruitment to therapeutic trials

Authors: Victoria V. Anwuri, Lannis E. Hall, Katherine Mathews, Brian C. Springer, Jennifer R. Tappenden, Dione M. Farria, Sherrill Jackson, Melody S. Goodman, Timothy J. Eberlein, Graham A. Colditz

Published in: Cancer Causes & Control | Issue 10/2013

Login to get access

Abstract

Purpose

Participation in therapeutic clinical trials rarely reflects the race and ethnic composition of the patient population. To meet National Institutes of Health-mandated goals, strategies to increase participation are required. We present a framework for institutional enhancement of minority clinical trial accrual.

Methods

We implemented structural changes on four levels to induce and sustain minority accrual to clinical trials: (1) leadership support; (2) center-wide policy change; (3) infrastructural process control, data analysis, and reporting; and (4) follow-up with clinical investigators. A Protocol Review and Monitoring Committee reviews studies and monitors accrual, and the Program for the Elimination Cancer Disparities leads efforts for proportional accrual, supporting the system through data tracking, Web tools, and feedback to investigators.

Results

Following implementation in 2005, minority accrual to therapeutic trials increased from 12.0 % in 2005 to 14.0 % in 2010. The “rolling average” minority cancer incidence at the institution during this timeframe was 17.5 %. In addition to therapeutic trial accrual rates, we note significant increase in the number of minorities participating in all trials (therapeutic and nontherapeutic) from 2005 to 2010 (346–552, 60 % increase, p < 0.05) compared to a 52 % increase for Caucasians.

Conclusions

Implementing a system to aid investigators in planning and establishing targets for accrual, while requiring this component as a part of annual protocol review and monitoring of accrual, offers a successful strategy that can be replicated in other cancer centers, an approach that may extend to other clinical and translational research centers.
Appendix
Available only for authorised users
Footnotes
1
The Quality Assurance and Safety Monitoring Committee (QASMC) provides independent oversight and review of quality assurance audits, serious adverse event reporting, and interim data and safety monitoring reports.
 
2
Ancillary, chart review, companion, correlative, detection (early), diagnostic (non-radiologic), diagnostic imaging, epidemiologic, exempt research, existing data/specimens, observational, prevention and control, registry, screening, standard treatment, supportive care, survey, therapeutic, tissue/specimen, tissue/survey.
 
3
AIDS-related, chemoprevention-related, psychosocial factors in cancer care, nicotine dependence, community outreach and prevention, early detection and screening, ecological aspects of early detection and cancer care, other, null.
 
Literature
1.
Freedman LS, Simon R, Foulkes MA, et al (1995) Inclusion of women and minorities in clinical trials and the NIH revitalization act of 1993—the perspective of NIH clinical trials. Control Clin Trials 16:277–285. Discussion 86-9, 93-309
2.
Hohmann AA, Parron DL (1996) How the new NIH guidelines on inclusion of women and minorities apply: efficacy trials, effectiveness trials, and validity. J Consult Clin Psychol 64:851–855PubMedCrossRef
3.
(June 10, 1993) NIH Revitalization Act of 1993
4.
(October 9, 2001) Amendment: NIH Policy and Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research, October 2001
5.
Christian MC, Trimble EL (2003) Increasing participation of physicians and patients from underrepresented racial and ethnic groups in National Cancer Institute-sponsored clinical trials. Cancer Epidemiol Biomarkers Prev 12:S277–S283
6.
Murthy VH, Krumholz HM, Gross CP (2004) Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 291:2720–2726PubMedCrossRef
7.
Stewart JH, Bertoni AG, Staten JL, Levine EA, Gross CP (2007) Participation in surgical oncology clinical trials: gender-, race/ethnicity-, and age-based disparities. Ann Surg Oncol 14:3328–3334PubMedCrossRef
8.
Baquet CR, Ellison GL, Mishra SI (2008) Analysis of Maryland cancer patient participation in national cancer institute-supported cancer treatment clinical trials. J Clin Oncol 26:3380–3386PubMedCrossRef
9.
National Cancer Institute (2000) NCI-supported clinical trials: facts and figures. National Cancer Institute, Rockville
10.
Movsas B, Moughan J, Owen J et al (2007) Who enrolls onto clinical oncology trials? A radiation patterns of care study analysis. Int J Radiat Oncol Biol Phys 68:1145–1150PubMedCrossRef
11.
Springfield S (2010) Racial and ethnic minorities accrual to NCI clinical trials. Center to Reduce Cancer Health Disparities, National Cancer Institute, NIH, Bethesdda, MD
12.
US Bureau of the Census (2000) DP-1. Profile of general demographic characteristics: 2000. Census 2000 summary file 1 (SF 1) 100-percent data. US Census Bureau
13.
Sateren WB, Trimble EL, Abrams J et al (2002) How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol 20:2109–2117PubMedCrossRef
14.
Elliott TE, Elliott BA, Renier CM, Haller IV (2004) Rural-urban differences in cancer care: results from the lake superior rural cancer care project. Minn Med 87:44–50PubMed
15.
Klabunde CN, Springer BC, Butler B, White MS, Atkins J (1999) Factors influencing enrollment in clinical trials for cancer treatment. South Med J 92:1189–1193PubMedCrossRef
16.
Ford JG, Howerton MW, Bolen S, et al (2005) Knowledge and access to information on recruitment of underrepresented populations to cancer clinical trials. Evidence report/technology assessment (Summ), pp 1–11
17.
Tournoux C, Katsahian S, Chevret S, Levy V (2006) Factors influencing inclusion of patients with malignancies in clinical trials. Cancer 106:258–270PubMedCrossRef
18.
Ford JG, Howerton MW, Lai GY et al (2008) Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer 112:228–242PubMedCrossRef
19.
Adams-Campbell LL, Ahaghotu C, Gaskins M et al (2004) Enrollment of African Americans onto clinical treatment trials: study design barriers. J Clin Oncol 22:730–734PubMedCrossRef
20.
Holcombe RF, Jacobson J, Li A, Moinpour CM (1999) Inclusion of black Americans in oncology clinical trials: the Louisiana State University Medical Center experience. Am J Clin Oncol 22:18–21PubMedCrossRef
21.
Baquet CR, Commiskey P, Daniel Mullins C, Mishra SI (2006) Recruitment and participation in clinical trials: socio-demographic, rural/urban, and health care access predictors. Cancer Detect Prev 30:24–33PubMedCrossRef
22.
Robinson SB, Ashley M, Haynes MA (1996) Attitude of African-Americans regarding prostate cancer clinical trials. J Community Health 21:77–87PubMedCrossRef
23.
Coyne CA, Demian-Popescu C, Brown P (2004) Rural cancer patients’ perspectives on clinical trials: a qualitative study. J Cancer Educ 19:165–169PubMedCrossRef
24.
Brown DR, Fouad MN, Basen-Engquist K, Tortolero-Luna G (2000) Recruitment and retention of minority women in cancer screening, prevention, and treatment trials. Ann Epidemiol 10:S13–S21PubMedCrossRef
25.
Pinto HA, McCaskill-Stevens W, Wolfe P, Marcus AC (2000) Physician perspectives on increasing minorities in cancer clinical trials: an Eastern Cooperative Oncology Group (ECOG) Initiative. Ann Epidemiol 10:S78–S84PubMedCrossRef
26.
Advani AS, Atkeson B, Brown CL et al (2003) Barriers to the participation of African-American patients with cancer in clinical trials: a pilot study. Cancer 97:1499–1506PubMedCrossRef
27.
Outlaw FH, Bourjolly JN, Barg FK (2000) A study on recruitment of black Americans into clinical trials through a cultural competence lens. Cancer Nurs 23:444–451. quiz 51-2
28.
Hudson SV, Momperousse D, Leventhal H (2005) Physician perspectives on cancer clinical trials and barriers to minority recruitment. Cancer Control 12:S93–S96
29.
Giuliano AR, Mokuau N, Hughes C et al (2000) Participation of minorities in cancer research: the influence of structural, cultural, and linguistic factors. Ann Epidemiol 10:S22–S34PubMedCrossRef
30.
Linden HM, Reisch LM, Hart A Jr et al (2007) Attitudes toward participation in breast cancer randomized clinical trials in the African American community: a focus group study. Cancer Nurs 30:261–269PubMedCrossRef
31.
Shavers VL, Lynch CF, Burmeister LF (2002) Racial differences in factors that influence the willingness to participate in medical research studies. Ann Epidemiol 12:248–256PubMedCrossRef
32.
George SL (1996) Reducing patient eligibility criteria in cancer clinical trials. J Clin Oncol 14:1364–1370PubMed
33.
Fuks A, Weijer C, Freedman B, Shapiro S, Skrutkowska M, Riaz A (1998) A study in contrasts: eligibility criteria in a twenty-year sample of NSABP and POG clinical trials. J Clin Epidemiol 51:69–79PubMedCrossRef
34.
McCabe MS, Varricchio CG, Padberg RM (1994) Efforts to recruit the economically disadvantaged to national clinical trials. Semin Oncol Nurs 10:123–129PubMedCrossRef
35.
Elks ML (1993) The right to participate in research studies. J Lab Clin Med 122:130–136PubMed
36.
Townsley CA, Selby R, Siu LL (2005) Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol 23:3112–3124PubMedCrossRef
37.
Swanson GM, Bailar JC 3rd (2002) Selection and description of cancer clinical trials participants–science or happenstance? Cancer 95:950–959PubMedCrossRef
38.
Wood CG, Wei SJ, Hampshire MK, Devine PA, Metz JM (2006) The influence of race on the attitudes of radiation oncology patients towards clinical trial enrollment. Am J Clin Oncol 29:593–599PubMedCrossRef
39.
Fracasso PM, Walker MS, Mathews KJ et al (2007) Coaching intervention as a strategy for enhancing accrual to phase I/II clinical trials. J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I 25:S6580
40.
Fouad MN, Partridge E, Green BL et al (2000) Minority recruitment in clinical trials: a conference at Tuskegee, researchers and the community. Ann Epidemiol 10:S35–S40PubMedCrossRef
41.
Fouad MN, Partridge E, Wynn T, Green BL, Kohler C, Nagy S (2001) Statewide Tuskegee alliance for clinical trials. A community coalition to enhance minority participation in medical research. Cancer 91:237–241PubMedCrossRef
42.
Lai GY, Gary TL, Tilburt J et al (2006) Effectiveness of strategies to recruit underrepresented populations into cancer clinical trials. Clin Trials 3:133–141PubMedCrossRef
43.
Sorensen G, Emmons K, Hunt MK et al (2003) Model for incorporating social context in health behavior interventions: applications for cancer prevention for working-class, multiethnic populations. Prev Med 37:188–197PubMedCrossRef
44.
Emmons K (2000) Behavioral and social science contributions to the health of adults in the United States. In: Smedley BD, Syme SL (eds) Promoting health: intervention strategies from social and behavioral research. The National Academies Press, Washington, DC, pp 254–321
45.
Stetler CB, Mittman BS, Francis J (2008) Overview of the VA Quality Enhancement Research Initiative (QUERI) and QUERI theme articles: QUERI Series. Implement Sci 3:8PubMedCrossRef
46.
Stetler CB, McQueen L, Demakis J, Mittman BS (2008) An organizational framework and strategic implementation for system-level change to enhance research-based practice: QUERI Series. Implement Sci 3:30PubMedCrossRef
47.
Feussner JR, Kizer KW, Demakis JG (2000) The Quality Enhancement Research Initiative (QUERI): from evidence to action. Med Care 38:I1–I6PubMedCrossRef
48.
Siteman Cancer Center (2011) Institutional data safety and monitoring plan. Siteman Cancer Center, St. Louis
49.
Percy C, Fritz A, Jack A et al (1976) International classification of diseases for oncology (ICD-O), 3rd (ICD-O-3) edn. World Health Organization, Geneva Switzerland
50.
Morgenlander KH, Winters SB, Lin CJ, Robertson LB, Heron DE, Herberman RB (2008) Novel method for benchmarking recruitment of African American cancer patients to clinical therapeutic trials. J Clin Oncol 26:5074–5077PubMedCrossRef
51.
Siteman Cancer Center (2009) Monitoring accrual by gender: race and ethnicity. Siteman Cancer Center, St. Louis
52.
Wright JR, Bouma S, Dayes I et al (2006) The importance of reporting patient recruitment details in phase III trials. J Clin Oncol 24:843–845PubMedCrossRef
53.
Corbie-Smith G, St George DM, Moody-Ayers S, Ransohoff DF (2003) Adequacy of reporting race/ethnicity in clinical trials in areas of health disparities. J Clin Epidemiol 56:416–420PubMedCrossRef
54.
Committee on Assuring the Health of the Public in the 21st Century, Board on Health Promotion and Disease Prevention, Institute of Medicine of the National Academies (2002) The Future of the Public’s Health in the 21st Century. The National Academies Press, Washington, DC
55.
Wagner EH (1998) Chronic disease management: what will it take to improve care for chronic illness? Eff Clin Pract 1:2–4PubMed
Metadata
Title
An institutional strategy to increase minority recruitment to therapeutic trials
Authors
Victoria V. Anwuri
Lannis E. Hall
Katherine Mathews
Brian C. Springer
Jennifer R. Tappenden
Dione M. Farria
Sherrill Jackson
Melody S. Goodman
Timothy J. Eberlein
Graham A. Colditz
Publication date
01-10-2013
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 10/2013
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-013-0258-1

Other articles of this Issue 10/2013

Cancer Causes & Control 10/2013 Go to the issue

Original paper

Circulating C-peptide level is a predictive factor for colorectal neoplasia: evidence from the meta-analysis of prospective studies

Original paper

Genetic variants in ARID5B and CEBPE are childhood ALL susceptibility loci in Hispanics

Original paper

Case–control analysis on metformin and cancer of the esophagus

OriginalPaper

The California Breast Cancer Survivorship Consortium (CBCSC): prognostic factors associated with racial/ethnic differences in breast cancer survival

Brief report

Joint effects between five identified risk variants, allergy, and autoimmune conditions on glioma risk

Original paper

Early life factors and adult mammographic density
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits